Gijón (Spain) and Guimarães (Portugal) – October 2nd, 2019
Gistem Research SL has signed an agreement with the Portuguese CDMO Stemmatters SA that will cover the manufacturing of Gistem´s novel stem cell-derived therapy for the treatment of dry eye. According to the agreement, Stemmatters is responsible for the transfer process, scale-up, process validation and cGMP production for the phaseI/II clinical trial.
Rui Sousa, CEO of Stemmatters, added “We are extremely motivated to contribute to the clinical translation of such innovative therapy”.
“As we advance our lead candidate into clinical development, we look forward to having Stemmatters as an appreciated, flexible and reliable service partner that delivers on its promises”, said Francisco Vizoso, Gistem´s founder.
GiStem Research (Gijon, Spain) is a privately-owned company developing innovative therapies derived from their proprietary human Uterine Cervical Stem Cells (hUCESCs) platform, a novel source of mesenchymal stem cells showing facile cell isolation protocol, high manufacturing process scalability, and immunoregulatory activity. More information available at: www.gistemresearch.com
Stemmatters, SA (Guimarães, Portugal) is an integrated biotechnology company that develops and manufactures novel biological and advanced therapy products. The company implements has expertise in design and formulation of new combination products, for which Stemmatters can implement and assure GMP-compliant manufacturing for first-in-human clinical studies or commercial supply programs. For company information, please visit: http://www.stemmatters.com/
Phone: +34 984 991 074
Phone: +351 253 540 100